Being a Pioneer in Genomic Drug Discovery
When mapping and sequencing the human genome was reported complete in 2003, there were heightened expectations in the world for discovery of innovative new drugs that took advantage of the latest genome research findings. In reality, however, we haven't seen any remarkable achievement so far despite enormous amount of investment.
Forerunner Pharma Research (FPR) was founded to break out of such stagnant situation. Our mission is to deliver revolutionary new medicines to the hand of medical professionals as fast as possible. We intend to make this happen by creating an unprecedented research collaboration form in which we mobilize knowledge and findings of genome-centered fundamental research, biopharmaceutical technology and pathological and disease structure studies.
As a step towards fulfillment of our mission, we started well-rounded collaborative research with Research Center for Advanced Science and Technology (RCAST), the University of Tokyo. With proven records in leading-edge researches, RCAST is a perfect research partner to FPR.
FPR is committed to be a pioneer in the field of genome-based new drug discovery, specifically antibody drugs for cancer diagnostics and therapeutics.
Tatsumi Yamazaki, Ph.D.
President, Forerunner Pharma Research Co., Ltd.
